Addressing the funding gap to advance early stage healthcare research at the University of Sheffield
Lead Research Organisation:
University of Sheffield
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
People |
ORCID iD |
Publications
Elhaik E
(2016)
A "Wear and Tear" Hypothesis to Explain Sudden Infant Death Syndrome.
in Frontiers in neurology
Rust A
(2017)
A Cell Line for Detection of Botulinum Neurotoxin Type B.
in Frontiers in pharmacology
Al-Hameed S
(2019)
A new diagnostic approach for the identification of patients with neurodegenerative cognitive complaints.
in PloS one
Easton K
(2019)
A Virtual Agent to Support Individuals Living With Physical and Mental Comorbidities: Co-Design and Acceptability Testing.
in Journal of medical Internet research
Doran C
(2018)
An enzymatic reporter cell line for detection of botulinum neurotoxin type B
in Toxicon
Esposito U
(2018)
Ancient Ancestry Informative Markers for Identifying Fine-Scale Ancient Population Structure in Eurasians.
in Genes
Mirheidari B
(2019)
Dementia detection using automatic analysis of conversations
in Computer Speech & Language
Alqarni AM
(2020)
How does methotrexate work?
in Biochemical Society transactions
Frith TJ
(2018)
Human axial progenitors generate trunk neural crest cells in vitro.
in eLife
Elhaik E
(2016)
In Search of the jüdische Typus: A Proposed Benchmark to Test the Genetic Basis of Jewishness Challenges Notions of "Jewish Biomarkers".
in Frontiers in genetics
Gremese E
(2019)
JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy.
in Journal of leukocyte biology
Das R
(2016)
Localizing Ashkenazic Jews to Primeval Villages in the Ancient Iranian Lands of Ashkenaz.
in Genome biology and evolution
Chinnaiya K
(2017)
Low-dose methotrexate in myeloproliferative neoplasm models.
in Haematologica
Francis S
(2019)
Low-dose methotrexate: potential clinical impact on haematological and constitutional symptoms in myeloproliferative neoplasms.
in British journal of haematology
Elhaik E
(2019)
Pair Matcher (PaM): fast model-based optimization of treatment/case-control matches.
in Bioinformatics (Oxford, England)
Marshall S
(2016)
Reconstructing Druze population history.
in Scientific reports
Frith TJR
(2020)
Retinoic Acid Accelerates the Specification of Enteric Neural Progenitors from In-Vitro-Derived Neural Crest.
in Stem cell reports
Das R
(2017)
The Origins of Ashkenaz, Ashkenazic Jews, and Yiddish.
in Frontiers in genetics
Hackland JOS
(2017)
Top-Down Inhibition of BMP Signaling Enables Robust Induction of hPSCs Into Neural Crest in Fully Defined, Xeno-free Conditions.
in Stem cell reports
Morozova I
(2016)
Toward high-resolution population genomics using archaeological samples.
in DNA research : an international journal for rapid publication of reports on genes and genomes
| Description | A highly sensitive replacement assay for botulinum neurotoxin type B |
| Amount | £306,073 (GBP) |
| Funding ID | NC/S000925/1 |
| Organisation | National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2018 |
| End | 01/2021 |
| Description | Collaborative R&D |
| Amount | £230,000 (GBP) |
| Organisation | Bloodwise |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | IPDaC - Maintaining Confidentiality |
| Amount | £70,000 (GBP) |
| Organisation | University of Sheffield |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 11/2018 |
| End | 11/2019 |
| Description | ITN |
| Amount | € 3,800,000 (EUR) |
| Funding ID | 766287 |
| Organisation | European Commission |
| Department | Horizon 2020 |
| Sector | Public |
| Country | European Union (EU) |
| Start | |
| Description | International Research Grant |
| Amount | £159,900 (GBP) |
| Organisation | Action on Hearing Loss |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2016 |
| End | 07/2019 |
| Description | MRC Proximity to Discover Scheme via University of Sheffield |
| Amount | £36,000 (GBP) |
| Funding ID | 157034 |
| Organisation | University of Sheffield |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 07/2018 |
| End | 12/2018 |
| Description | NIRG: Taming the skew - empowering Mendelian randomization trials by controlling stratification bias |
| Amount | £427,435 (GBP) |
| Funding ID | MR/R025126/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2018 |
| End | 07/2021 |
| Description | Collaborator on a project awarded under The University of Sheffield's institutional award from Round 3 of the Confidence in Concept Scheme |
| Organisation | JRI Orthapaedics |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Lead on project looking at biomimetic, medical implants to promote in situ repair of traumatic and early osteoarthritic cartilage defects |
| Collaborator Contribution | Provision of technical advice. |
| Impact | Exploring further opportunities. |
| Start Year | 2015 |
| Description | Collaborator on a project awarded under The University of Sheffield's institutional award from Round 3 of the Confidence in Concept Scheme |
| Organisation | The Electrospinning Company |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Lead on on project looking at Biomimetic, medical implants to promote in situ repair of traumatic and early osteoarthritic cartilage defects |
| Collaborator Contribution | Provision of scaffold materials. |
| Impact | Discussion on further opportunities. |
| Start Year | 2015 |
| Title | HUMAN OTIC PROGENITOR IDENTIFICATION AND ISOLATION |
| Description | The present invention relates generally to the identification and isolation of human otic progenitor cells. More specifically, the present invention relates to a method of using cell markers to identify and isolate human otic progenitor cells from a mixed population of cells, methods of enrichment and production of human otic progenitor cells, and associated kits for use in identification and/or isolation of human otic progenitor cells, wherein the cell markers are selected from SSEA1 (CD15), disialoganglioside GD3, TRA-2-49 (liver/bone/ kidney alkaline phosphatase), SSEA4, ganglioside GD2 and CD141. |
| IP Reference | WO2018051092 |
| Protection | Patent granted |
| Year Protection Granted | 2018 |
| Licensed | Commercial In Confidence |
| Impact | Commercial In Confidence |
| Title | MEDICAL IMPLANT |
| Description | The present invention relates to a cell-free, multi-layered medical device having bespoke, multifunctional bioactivity for the purpose of regeneration of skeletal tissues. The medical device may actively promote homing of stem cells into the medical device and promote their differentiation into the required cell type and promote de-novo tissue formation. The invention includes methods of making the medical device, uses of the medical device in promoting regeneration of the articular cartilage of a joint surface and in promoting healing and regeneration of skeletal tissues, for example, meniscal cartilage, tendon and ligament tissues and also healing of bone tissue indications such as fractures. |
| IP Reference | WO2017017425 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | Commercial In Confidence |
| Impact | Commercial In Confidence |
| Title | METHOD FOR PRODUCING OTIC PROGENITORS |
| Description | This invention relates to an improved method for generating otic progenitor cells. The invention also relates to uses of such otic progenitor cells, for example as a medicament (e.g. in the treatment of hearing loss, deafness or other auditory disorder associated with loss of inner ear function) and/or in drug screening methods. |
| IP Reference | WO2016156831 |
| Protection | Patent granted |
| Year Protection Granted | 2016 |
| Licensed | Commercial In Confidence |
| Impact | Commercial in Confidence |
| Title | STABLE VAMP REPORTER ASSAY |
| Description | The present invention provides a polypeptide comprising an N-terminal polypeptide domain having luciferase activity and a C-terminal polypeptide domain having VAMP1, VAMP2 or VAMP3 activity where VAMP stands for vesicle-associated membrane protein. Corresponding nucleic acid molecules, expression vectors and genetically modified cells are also provided. The invention also provides methods and uses of the same. |
| IP Reference | WO2018150177 |
| Protection | Patent granted |
| Year Protection Granted | 2018 |
| Licensed | Commercial In Confidence |
| Impact | Commercial In Confidence |
| Company Name | RINRI THERAPEUTICS LIMITED |
| Description | Commercial In Confidence |
| Year Established | 2018 |
| Impact | Commercial In Confidence |